Browse

You are looking at 81 - 90 of 2,633 items for

  • Refine by access: All content x
Clear All
Clarissa Wormsbaecher Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, USA
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Clarissa Wormsbaecher in
Google Scholar
PubMed
Close
,
Brittney M Cumbia The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Brittney M Cumbia in
Google Scholar
PubMed
Close
,
Emma G Amurgis The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Emma G Amurgis in
Google Scholar
PubMed
Close
,
Jillian M Poska Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, USA
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Jillian M Poska in
Google Scholar
PubMed
Close
,
Madeline R Price Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, USA
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Madeline R Price in
Google Scholar
PubMed
Close
,
Xiaokui M Mo Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

Search for other papers by Xiaokui M Mo in
Google Scholar
PubMed
Close
,
Sue E Knoblaugh Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA

Search for other papers by Sue E Knoblaugh in
Google Scholar
PubMed
Close
,
Takeshi Kurita The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
Department of Cancer Biology and Genetics, The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA

Search for other papers by Takeshi Kurita in
Google Scholar
PubMed
Close
, and
Craig Joseph Burd Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, USA
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Craig Joseph Burd in
Google Scholar
PubMed
Close

Development of the mammary gland requires both proper hormone signaling and cross talk between the stroma and epithelium. While estrogen receptor (ERα) expression in the epithelium is essential for normal gland development, the role of this receptor in the stroma is less clear. Moreover, several lines of evidence suggest that mouse phenotypes of in utero exposure to endocrine disruption act through mesenchymal ERα in the developing fetus. We utilized a Twist2-cre mouse line to knock out mesenchymal ERα. Herein, we assessed mammary gland development in the context of mesenchymal ERα deletion. We also tested the effect of in utero bisphenol A (BPA) exposure to alter the tumor susceptibility in the mouse mammary tumor virus-neu (MMTV-neu) breast cancer mouse model. Mesenchymal ERα deletion resulted in altered reproductive tract development and atypical cytology associated with estrous cycling. The mammary gland demonstrated mature epithelial extension unlike complete ERα-knockout mice, but ductal extension was delayed and reduced compared to ERα-competent mice. Using the MMTV-Neu cancer susceptibility model, ERα-intact mice exposed to BPA had reduced tumor-free survival and overall survival compared to BPA-exposed mice having mesenchymal ERα deletion. This difference is specific for BPA exposure as vehicle-treated animals had no difference in tumor development between mice expressing and not expressing mesenchymal ERα. These data demonstrate that mesenchymal ERα expression is not required for ductal extension, nor does it influence cancer risk in this mouse model but does influence the cancer incidence associated with in utero BPA exposure.

Restricted access
Minghao Li Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse, Dresden, Germany
Department of Urology, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Minghao Li in
Google Scholar
PubMed
Close
,
Susan Richter Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Search for other papers by Susan Richter in
Google Scholar
PubMed
Close
,
Hermine Mohr Institute for Diabetes and Cancer, Helmholtz Centre Munich, Neuherberg, Germany

Search for other papers by Hermine Mohr in
Google Scholar
PubMed
Close
,
Stephan Drukewitz Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany

Search for other papers by Stephan Drukewitz in
Google Scholar
PubMed
Close
,
Isabel Poser Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Search for other papers by Isabel Poser in
Google Scholar
PubMed
Close
,
Daniela Stanke Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Search for other papers by Daniela Stanke in
Google Scholar
PubMed
Close
,
Bruna Calsina Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

Search for other papers by Bruna Calsina in
Google Scholar
PubMed
Close
,
Angel M Martinez-Montes Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

Search for other papers by Angel M Martinez-Montes in
Google Scholar
PubMed
Close
,
Marcus Quinkler Endocrinology in Charlottenburg, Berlin, Germany

Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
Close
,
Henri J L M Timmers Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by Henri J L M Timmers in
Google Scholar
PubMed
Close
,
Svenja Nölting Medizinische Klinik Und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany
Department of Endocrinology, Diabetology and Clinical Nutrition, Universitätsspital Zürich (USZ) and University of Zurich (UZH), Zurich, Switzerland

Search for other papers by Svenja Nölting in
Google Scholar
PubMed
Close
,
Felix Beuschlein Medizinische Klinik Und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany
Department of Endocrinology, Diabetology and Clinical Nutrition, Universitätsspital Zürich (USZ) and University of Zurich (UZH), Zurich, Switzerland

Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Close
,
Hanna Remde Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital of Würzburg, Würzburg, Germany

Search for other papers by Hanna Remde in
Google Scholar
PubMed
Close
,
Giuseppe Opocher Department of Medicine, University of Padua, Padua, Italy

Search for other papers by Giuseppe Opocher in
Google Scholar
PubMed
Close
,
Elena Rapizzi Department of Experimental and Clinical Medicine, University of Florence, Italy

Search for other papers by Elena Rapizzi in
Google Scholar
PubMed
Close
,
Karel Pacak Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States

Search for other papers by Karel Pacak in
Google Scholar
PubMed
Close
,
Christina Pamporaki Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse, Dresden, Germany

Search for other papers by Christina Pamporaki in
Google Scholar
PubMed
Close
,
Mercedes Robledo Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Close
,
Longfei Liu Department of Urology, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Longfei Liu in
Google Scholar
PubMed
Close
,
Jingjing Jiang Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Jingjing Jiang in
Google Scholar
PubMed
Close
,
Stefan R Bornstein Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse, Dresden, Germany

Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Close
,
Graeme Eisenhofer Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse, Dresden, Germany

Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Close
,
Stephanie M J Fliedner University Cancer Center Schleswig-Holstein, University Medical Center Schleswig-Holsten, Lübeck, Germany

Search for other papers by Stephanie M J Fliedner in
Google Scholar
PubMed
Close
, and
Nicole Bechmann Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Search for other papers by Nicole Bechmann in
Google Scholar
PubMed
Close

The biochemical phenotype of paragangliomas (PGLs) is highly dependent on the underlying genetic background and tumor location. PGLs at extra-adrenal locations usually do not express phenylethanolamine N-methyltransferase (PNMT), the enzyme required for epinephrine production, which was explained by the absence of glucocorticoids. PGLs with pathogenic variants (PVs) in Harvey rat sarcoma viral oncogene homolog (HRAS) can occur in or outside of the adrenal, but always synthesize epinephrine independently of the localization. Here, we characterize the signaling pathways through which PVs in HRAS influence PNMT expression. Catecholamines, cortisol, and transcriptional features of PGL tissues with known genetic background were analyzed. Genetically modified rat pheochromocytoma cells carrying PVs in Hras were generated and analyzed for regulation of Pnmt expression. Elevated epinephrine contents in PGLs with PVs in HRAS were accompanied by enrichment in mitogen-activated protein kinase (MAPK) signaling compared to PGLs with PVs in genes that activate hypoxia pathways. In vitro, Hras PVs increased Pnmt expression and epinephrine biosynthesis through increased phosphorylation of stimulatory protein 1 via MAPK signaling. Here, we provide a molecular mechanism that explains the PV-dependent epinephrine production of PGLs.

Restricted access
Barbora Bulanova Pekova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Barbora Bulanova Pekova in
Google Scholar
PubMed
Close
,
Vlasta Sykorova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Vlasta Sykorova in
Google Scholar
PubMed
Close
,
Karolina Mastnikova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Karolina Mastnikova in
Google Scholar
PubMed
Close
,
Eliska Vaclavikova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Eliska Vaclavikova in
Google Scholar
PubMed
Close
,
Jitka Moravcova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Jitka Moravcova in
Google Scholar
PubMed
Close
,
Petr Vlcek Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Petr Vlcek in
Google Scholar
PubMed
Close
,
Lucie Lancova Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Lucie Lancova in
Google Scholar
PubMed
Close
,
Petr Lastuvka Departments of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Petr Lastuvka in
Google Scholar
PubMed
Close
,
Rami Katra Department of Ear, Nose and Throat, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Rami Katra in
Google Scholar
PubMed
Close
,
Petr Bavor Department of Surgery, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Petr Bavor in
Google Scholar
PubMed
Close
,
Daniela Kodetova Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Search for other papers by Daniela Kodetova in
Google Scholar
PubMed
Close
,
Martin Chovanec Department of Otorhinolaryngology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic

Search for other papers by Martin Chovanec in
Google Scholar
PubMed
Close
,
Jana Drozenova Department of Pathology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic

Search for other papers by Jana Drozenova in
Google Scholar
PubMed
Close
,
Radoslav Matej Department of Pathology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic

Search for other papers by Radoslav Matej in
Google Scholar
PubMed
Close
,
Jaromir Astl Department of Otorhinolaryngology and Maxillofacial Surgery, 3rd Faculty of Medicine and Military University Hospital, Prague, Czech Republic

Search for other papers by Jaromir Astl in
Google Scholar
PubMed
Close
,
Jiri Hlozek Department of Otorhinolaryngology and Maxillofacial Surgery, 3rd Faculty of Medicine and Military University Hospital, Prague, Czech Republic

Search for other papers by Jiri Hlozek in
Google Scholar
PubMed
Close
,
Petr Hrabal Department of Pathology, Military University Hospital, Prague, Czech Republic

Search for other papers by Petr Hrabal in
Google Scholar
PubMed
Close
,
Josef Vcelak Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Josef Vcelak in
Google Scholar
PubMed
Close
, and
Bela Bendlova Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic

Search for other papers by Bela Bendlova in
Google Scholar
PubMed
Close

Thyroid cancer is associated with a broad range of different mutations, including RET (rearranged during transfection) fusion genes. The importance of characterizing RET fusion-positive tumors has recently increased due to the possibility of targeted treatment. The aim of this study was to identify RET fusion-positive thyroid tumors, correlate them with clinicopathological features, compare them with other mutated carcinomas, and evaluate long-term follow-up of patients. The cohort consisted of 1564 different thyroid tissue samples (including 1164 thyroid carcinoma samples) from pediatric and adult patients. Samples were analyzed for known driver mutations occurring in thyroid cancer. Negative samples were subjected to extensive RET fusion gene analyses using next-generation sequencing and real-time PCR. RET fusion genes were not detected in any low-risk neoplasm or benign thyroid tissue and were detected only in papillary thyroid carcinomas (PTCs), in 113/993 (11.4%) patients, three times more frequently in pediatric and adolescent patients (29.8%) than in adult patients (8.7%). A total of 20 types of RET fusions were identified. RET fusion-positive carcinomas were associated with aggressive tumor behavior, including high rates of lymph node (75.2%) and distant metastases (18.6%), significantly higher than in NTRK fusion, BRAF V600E and RAS-positive carcinomas. Local and distant metastases were also frequently found in patients with microcarcinomas positive for the RET fusions. ’True recurrences’ occurred rarely (2.4%) and only in adult patients. The 2-, 5-, 10-year disease-specific survival rates were 99%, 96%, and 95%, respectively. RET fusion-positive carcinomas were associated with high invasiveness and metastatic activity, but probably due to intensive treatment with low patient mortality.

Open access
Parvin Yenki The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Parvin Yenki in
Google Scholar
PubMed
Close
,
Satyam Bhasin The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Satyam Bhasin in
Google Scholar
PubMed
Close
,
Liang Liu The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Liang Liu in
Google Scholar
PubMed
Close
,
Noushin Nabavi The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Noushin Nabavi in
Google Scholar
PubMed
Close
,
Chi Wing Cheng The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Chi Wing Cheng in
Google Scholar
PubMed
Close
,
Kevin J Tam The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Kevin J Tam in
Google Scholar
PubMed
Close
,
James W Peacock The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by James W Peacock in
Google Scholar
PubMed
Close
,
Hans H Adomat The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Hans H Adomat in
Google Scholar
PubMed
Close
,
Tabitha Tombe The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Tabitha Tombe in
Google Scholar
PubMed
Close
,
Ladan Fazli The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Close
,
Larissa Ivanova The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Larissa Ivanova in
Google Scholar
PubMed
Close
,
Christopher Dusek The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Christopher Dusek in
Google Scholar
PubMed
Close
,
Shahram Khosravi The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Shahram Khosravi in
Google Scholar
PubMed
Close
,
Emma S Tomlinson Guns The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

Search for other papers by Emma S Tomlinson Guns in
Google Scholar
PubMed
Close
,
Yuzhuo Wang The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Yuzhuo Wang in
Google Scholar
PubMed
Close
,
Ralph Buttyan The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Ralph Buttyan in
Google Scholar
PubMed
Close
,
Martin E Gleave The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Martin E Gleave in
Google Scholar
PubMed
Close
, and
Christopher J Ong The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Search for other papers by Christopher J Ong in
Google Scholar
PubMed
Close

Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that is highly expressed in castration-resistant prostate cancer, can promote steroidogenesis by altering the expression profile of key steroidogenic enzymes. Semaphorin 3C not only upregulates enzymes required for androgen synthesis from dehydroepiandrosterone or de novo from cholesterol but also simultaneously downregulates enzymes involved in the androgen inactivation pathway. These changes in gene expression correlate with increased production of androgens induced by semaphorin 3C in prostate cancer model cells. Moreover, semaphorin 3C upregulates androgen synthesis in LNCaP cell-derived xenograft tumors, likely contributing to the enhanced in vivo tumor growth rate post castration. Furthermore, semaphorin 3C activates sterol regulatory element-binding protein, a transcription factor that upregulates enzymes involved in the synthesis of cholesterol, a sole precursor for de novo steroidogenesis. The ability of semaphorin 3C to promote intratumoral androgen synthesis may be a key mechanism contributing to the reactivation of the androgen receptor pathway in castration-resistant prostate cancer, conferring continued growth under androgen deprivation therapy. These findings identify semaphorin 3C as a potential therapeutic target for suppressing intratumoral steroidogenesis.

Open access
Shu-Fu Lin Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
College of Medicine, Chang Gung University, Taoyuan, Taiwan

Search for other papers by Shu-Fu Lin in
Google Scholar
PubMed
Close
,
Yi-Yin Lee Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan

Search for other papers by Yi-Yin Lee in
Google Scholar
PubMed
Close
,
Ming-Hsien Wu Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan

Search for other papers by Ming-Hsien Wu in
Google Scholar
PubMed
Close
,
Yu-Ling Lu Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Search for other papers by Yu-Ling Lu in
Google Scholar
PubMed
Close
,
Chun-Nan Yeh Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Search for other papers by Chun-Nan Yeh in
Google Scholar
PubMed
Close
,
Wei-Yi Chen Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan

Search for other papers by Wei-Yi Chen in
Google Scholar
PubMed
Close
,
Ting-Chao Chou Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PD Science, Inc., Mill Run, Paramus, New Jersey, USA

Search for other papers by Ting-Chao Chou in
Google Scholar
PubMed
Close
, and
Richard J Wong Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Richard J Wong in
Google Scholar
PubMed
Close

Ataxia telangiectasia and Rad3-related protein (ATR) is a critical component of the DNA damage response and a potential target in the treatment of cancers. An ATR inhibitor, BAY 1895344, was evaluated for its use in differentiated thyroid cancer (DTC) therapy. BAY 1895344 inhibited cell viability in four DTC cell lines (TPC1, K1, FTC-133, and FTC-238) in a dose-dependent manner. BAY 1895344 treatment arrested DTC cells in the G2/M phase, increased caspase-3 activity, and caused apoptosis. BAY 1895344 in combination with either sorafenib or lenvatinib showed mainly synergistic effects in four DTC cell lines. The combination of BAY 1895344 with dabrafenib plus trametinib revealed synergistic effects in K1 cells that harbor BRAFV600E. BAY 1895344 monotherapy retarded the growth of K1 and FTC-133 tumors in xenograft models. The combinations of BAY 1895344 plus lenvatinib and BAY 1895344 with dabrafenib plus trametinib were more effective than any single therapy in a K1 xenograft model. No appreciable toxicity appeared in animals treated with either a single therapy or a combination treatment. Our findings provide the rationale for the development of clinical trials of BAY 1895344 in the treatment of DTC.

Restricted access
Angel Chao Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Angel Chao in
Google Scholar
PubMed
Close
,
Huei-Jean Huang Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Huei-Jean Huang in
Google Scholar
PubMed
Close
,
Chiao-Yun Lin Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Chiao-Yun Lin in
Google Scholar
PubMed
Close
,
Chia-Hwa Lee Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Chia-Hwa Lee in
Google Scholar
PubMed
Close
,
Chien-Hsing Lin Taiwan Genomic Industry Alliance Inc., Taipei, Taiwan

Search for other papers by Chien-Hsing Lin in
Google Scholar
PubMed
Close
,
An-Shine Chao Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Department of Obstetrics and Gynecology, New Taipei Municipal Tu Cheng Hospital, New Taipei City, Taiwan

Search for other papers by An-Shine Chao in
Google Scholar
PubMed
Close
,
Chyong-Huey Lai Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Chyong-Huey Lai in
Google Scholar
PubMed
Close
,
Ting-Chang Chang Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Ting-Chang Chang in
Google Scholar
PubMed
Close
,
Kai-Yun Wu Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Kai-Yun Wu in
Google Scholar
PubMed
Close
, and
Ren-Chin Wu Gynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan
Department of Anatomic Pathology, Linkou Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan

Search for other papers by Ren-Chin Wu in
Google Scholar
PubMed
Close

Steroid cell tumors, not otherwise specified (SCT-NOS), are uncommon ovarian neoplasms accompanied by virilization symptoms due to hyperandrogenism, which are malignant in approximately one-third of the cases. Given the rarity of SCT-NOS, their molecular underpinnings have not yet been studied in depth. In this case series, we performed the first comprehensive analysis of the genetic landscape of this rare ovarian tumor. A detailed clinicopathological description of an index case is also provided. Over a 20-year period, a total of eight patients were seen at our institution. Total nucleic acids (RNA and DNA) were extracted from evaluable formalin-fixed, paraffin-embedded tumor specimens (n = 7) and subjected to TruSight Oncology 500 testing and/or exome sequencing. The results identified pathogenic variants in several hypoxia-related genes – including HIF1A, VHL, SDHB, SRC, IDH2, and FOXO4. As the first comprehensive genetic analysis of SCT-NOS, this study shows that dysregulation in the hypoxia signaling pathway is a key molecular feature of this rare tumor. Clinically, long-term follow-up with periodic measurements of androgen levels should be pursued in all cases since recurrences may occur several years after the initial diagnosis.

Restricted access
Praful Ravi Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Search for other papers by Praful Ravi in
Google Scholar
PubMed
Close
,
Victoria Wang Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Search for other papers by Victoria Wang in
Google Scholar
PubMed
Close
,
Raina N Fichorova Department of Obstetrics, Gynecology and Reproductive Biology, Brigham & Women’s Hospital, Boston, Massachusetts, USA

Search for other papers by Raina N Fichorova in
Google Scholar
PubMed
Close
,
Bradley McGregor Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Search for other papers by Bradley McGregor in
Google Scholar
PubMed
Close
,
Xiao X Wei Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Search for other papers by Xiao X Wei in
Google Scholar
PubMed
Close
,
Shehzad Basaria Division of Endocrinology, Diabetes and Hypertension, Brigham & Women’s Hospital, Boston, Massachusetts, USA

Search for other papers by Shehzad Basaria in
Google Scholar
PubMed
Close
, and
Christopher J Sweeney South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia

Search for other papers by Christopher J Sweeney in
Google Scholar
PubMed
Close

Androgen deprivation therapy (ADT) forms the cornerstone of treatment in locally advanced and metastatic prostate cancer (PCa). Since the growth hormone–insulin-like growth factor (GH–IGF-1) axis has been implicated in prostate tumorigenesis, we aimed to evaluate the association between IGF-1 and its binding proteins on outcomes in men with metastatic PCa treated with ADT, with or without docetaxel (D). We analyzed serum samples for IGF-1 and its family proteins from baseline, 6 months post-randomization, and at the time of progression in men enrolled to receive ADT +/− D in the phase 3 CHAARTED trial. The key outcomes were time to the development of castrate-resistant prostate cancer and overall survival (OS). About 560 patients had samples available for analysis. At 6 months, significant increases in IGF-BP1 (mean Δ+27.4%, P = 0.033), IGF-BP3 (mean Δ+10.3%, P < 0.001), and IGF-BP4 (mean Δ+31.1%, P < 0.001) were seen in the ADT + D group, while the ADT group showed an increase in IGF-BP3 (mean Δ+5.5%, P = 0.015). A higher IGF-1:IGF-BP1 ratio at baseline and after 6 months was associated with improved OS in both the ADT (baseline: hazard ratio (HR) = 0.77, P = 0.026; 6 months: HR = 0.83, P = 0.036) and ADT + D groups (baseline: HR = 0.78, P = 0.04; 6 months: HR = 0.81, P = 0.018). Patients with a log10IGF-1:IGF-BP1 ratio >1.3 at baseline had improved OS when meta-analyzed with data from a prior cohort (HR = 0.71). A higher baseline and 6-month IGF-1:IGF-BP1 ratio was associated with better OS. Further exploration of the IGF-1 axis will be important to assess its role as a predictive biomarker and to target this axis in therapeutic trials.

Restricted access
Belinda J Petri Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Belinda J Petri in
Google Scholar
PubMed
Close
,
Kellianne M Piell Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Kellianne M Piell in
Google Scholar
PubMed
Close
,
Ali E Wilt Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Ali E Wilt in
Google Scholar
PubMed
Close
,
Alexa D Howser Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Alexa D Howser in
Google Scholar
PubMed
Close
,
Laura Winkler Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Laura Winkler in
Google Scholar
PubMed
Close
,
Mattie R Whitworth Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Mattie R Whitworth in
Google Scholar
PubMed
Close
,
Bailey L Valdes Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA

Search for other papers by Bailey L Valdes in
Google Scholar
PubMed
Close
,
Norman L Lehman Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA
Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky, USA
The Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA

Search for other papers by Norman L Lehman in
Google Scholar
PubMed
Close
,
Brian F Clem Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA
The Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA

Search for other papers by Brian F Clem in
Google Scholar
PubMed
Close
, and
Carolyn M Klinge Department of Biochemistry & Molecular Genetics, University of Louisville School of Medicine Louisville, Kentucky, USA
The Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA
Center for Integrative Environmental Health Sciences (CIEHS), University of Louisville, Louisville, Kentucky, USA

Search for other papers by Carolyn M Klinge in
Google Scholar
PubMed
Close

Despite the successful combination of therapies improving survival of estrogen receptor α (ER+) breast cancer patients with metastatic disease, mechanisms for acquired endocrine resistance remain to be fully elucidated. The RNA binding protein HNRNPA2B1 (A2B1), a reader of N(6)-methyladenosine (m6A) in transcribed RNA, is upregulated in endocrine-resistant, ER+ LCC9 and LY2 cells compared to parental MCF-7 endocrine-sensitive luminal A breast cancer cells. The miRNA-seq transcriptome of MCF-7 cells overexpressing A2B1 identified the serine metabolic processes pathway. Increased expression of two key enzymes in the serine synthesis pathway (SSP), phosphoserine aminotransferase 1 (PSAT1) and phosphoglycerate dehydrogenase (PHGDH), correlates with poor outcomes in ER+ breast patients who received tamoxifen (TAM). We reported that PSAT1 and PHGDH were higher in LCC9 and LY2 cells compared to MCF-7 cells and their knockdown enhanced TAM sensitivity in these-resistant cells. Here we demonstrate that stable, modest overexpression of A2B1 in MCF-7 cells increased PSAT1 and PHGDH and endocrine resistance. We identified four miRNAs downregulated in MCF-7-A2B1 cells that directly target the PSAT1 3′UTR (miR-145-5p and miR-424-5p), and the PHGDH 3′UTR (miR-34b-5p and miR-876-5p) in dual luciferase assays. Lower expression of miR-145-5p and miR-424-5p in LCC9 and ZR-75-1-4-OHT cells correlated with increased PSAT1 and lower expression of miR-34b-5p and miR-876-5p in LCC9 and ZR-75-1-4-OHT cells correlated with increased PHGDH. Transient transfection of these miRNAs restored endocrine-therapy sensitivity in LCC9 and ZR-75-1-4-OHT cells. Overall, our data suggest a role for decreased A2B1-regulated miRNAs in endocrine resistance and upregulation of the SSP to promote tumor progression in ER+ breast cancer.

Restricted access
Sonia M Abuzakhm OhioHealth, Columbus, Ohio, USA

Search for other papers by Sonia M Abuzakhm in
Google Scholar
PubMed
Close
,
Vineeth Sukrithan The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Vineeth Sukrithan in
Google Scholar
PubMed
Close
,
Briant Fruth Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Briant Fruth in
Google Scholar
PubMed
Close
,
Rui Qin Janssen Pharmaceuticals, Raritan, New Jersey, USA

Search for other papers by Rui Qin in
Google Scholar
PubMed
Close
,
Jonathan Strosberg H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Close
,
Timothy J Hobday Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Timothy J Hobday in
Google Scholar
PubMed
Close
,
Thomas Semrad Tahoe Forest Cancer Center, Truckee, California, USA

Search for other papers by Thomas Semrad in
Google Scholar
PubMed
Close
,
Diane Reidy-Lagunes Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed
Close
,
Hedy Lee Kindler University of Chicago Medical Center, Chicago, Illinois, USA

Search for other papers by Hedy Lee Kindler in
Google Scholar
PubMed
Close
,
George P Kim George Washington University Cancer Center, Washington, DC, USA

Search for other papers by George P Kim in
Google Scholar
PubMed
Close
,
Jennifer J Knox Princess Margaret Cancer Centre, Toronto, ON, Canada

Search for other papers by Jennifer J Knox in
Google Scholar
PubMed
Close
,
Andreas Kaubisch Montefiore Medical Center, Bronx, New York, USA

Search for other papers by Andreas Kaubisch in
Google Scholar
PubMed
Close
,
Miguel Villalona-Calero City of Hope, Duarte, California, USA

Search for other papers by Miguel Villalona-Calero in
Google Scholar
PubMed
Close
,
Helen Chen CTEP National Cancer Institute, Bethesda, Maryland, USA

Search for other papers by Helen Chen in
Google Scholar
PubMed
Close
,
Charles Erlichman Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Charles Erlichman in
Google Scholar
PubMed
Close
, and
Manisha H Shah The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Manisha H Shah in
Google Scholar
PubMed
Close

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.

Restricted access
Roberto Olmos Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Roberto Olmos in
Google Scholar
PubMed
Close
,
José Miguel Domínguez Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by José Miguel Domínguez in
Google Scholar
PubMed
Close
,
Sergio Vargas-Salas Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Sergio Vargas-Salas in
Google Scholar
PubMed
Close
,
Lorena Mosso Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Lorena Mosso in
Google Scholar
PubMed
Close
,
Carlos E Fardella Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Carlos E Fardella in
Google Scholar
PubMed
Close
,
Gilberto González Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Gilberto González in
Google Scholar
PubMed
Close
,
René Baudrand Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by René Baudrand in
Google Scholar
PubMed
Close
,
Francisco Guarda Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Francisco Guarda in
Google Scholar
PubMed
Close
,
Felipe Valenzuela Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Felipe Valenzuela in
Google Scholar
PubMed
Close
,
Eugenio Arteaga Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Eugenio Arteaga in
Google Scholar
PubMed
Close
,
Pablo Forenzano Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Pablo Forenzano in
Google Scholar
PubMed
Close
,
Flavia Nilo Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Flavia Nilo in
Google Scholar
PubMed
Close
,
Nicole Lustig Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Nicole Lustig in
Google Scholar
PubMed
Close
,
Alejandra Martínez Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Alejandra Martínez in
Google Scholar
PubMed
Close
,
José M López Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by José M López in
Google Scholar
PubMed
Close
,
Francisco Cruz Department of Radiology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Francisco Cruz in
Google Scholar
PubMed
Close
,
Soledad Loyola Department of Radiology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Soledad Loyola in
Google Scholar
PubMed
Close
,
Augusto Leon Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Augusto Leon in
Google Scholar
PubMed
Close
,
Nicolás Droppelmann Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Nicolás Droppelmann in
Google Scholar
PubMed
Close
,
Pablo Montero Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Pablo Montero in
Google Scholar
PubMed
Close
,
Francisco Domínguez Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Francisco Domínguez in
Google Scholar
PubMed
Close
,
Mauricio Camus Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Mauricio Camus in
Google Scholar
PubMed
Close
,
Antonieta Solar Department of Anatomic Pathology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Antonieta Solar in
Google Scholar
PubMed
Close
,
Pablo Zoroquiain Department of Anatomic Pathology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Pablo Zoroquiain in
Google Scholar
PubMed
Close
,
Juan Carlos Roa Department of Anatomic Pathology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Juan Carlos Roa in
Google Scholar
PubMed
Close
,
Estefanía Muñoz Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Estefanía Muñoz in
Google Scholar
PubMed
Close
,
Elsa Bruce Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Elsa Bruce in
Google Scholar
PubMed
Close
,
Rossio Gajardo Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Rossio Gajardo in
Google Scholar
PubMed
Close
,
Giovanna Miranda Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Giovanna Miranda in
Google Scholar
PubMed
Close
,
Francisco Riquelme Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Francisco Riquelme in
Google Scholar
PubMed
Close
,
Natalia Mena Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Natalia Mena in
Google Scholar
PubMed
Close
, and
Hernán E González Department of Surgical Oncology, School of Medicine Pontificia Universidad Católica de Chile

Search for other papers by Hernán E González in
Google Scholar
PubMed
Close

Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules (ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post-validation studies are necessary to determine the real-world clinical benefit of ThyroidPrint® in patients with ITN. A single-center, prospective, noninterventional clinical utility study was performed, analyzing the impact of ThyroidPrint® in the physicians’ clinical decisions for ITN. Demographics, nodule characteristics, benign call rates (BCRs), and surgical outcomes were measured. Histopathological data were collected from surgical biopsies of resected nodules. Of 1272 fine-needle aspirations, 109 (8.6%) were Bethesda III and 135 (10.6%) were Bethesda IV. Molecular testing was performed in 155 of 244 ITN (63.5%), of which 104 were classified as benign (BCR of 67.1%). After a median follow-up of 15 months, 103 of 104 (99.0%) patients with a benign ThyroidPrint® remained under surveillance and one patient underwent surgery which was a follicular adenoma. Surgery was performed in all 51 patients with a suspicious for malignancy as per ThyroidPrint® result and in 56 patients who did not undergo testing, with a rate of malignancy of 70.6% and 32.1%, respectively. A higher BCR was observed in follicular lesion of undetermined significance (87%) compared to atypia of undetermined significance (58%) (P < 0.05). False-positive cases included four benign follicular nodules and six follicular and four oncocytic adenomas. Our results show that, physicians chose active surveillance instead of diagnostic surgery in all patients with a benign ThyroidPrint® result, reducing the need for diagnostic surgery in 67% of patients with preoperative diagnosis of ITN.

Open access